Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer Technology appraisal guidance TA258 Published: 27 June 2012 Guidance Tools ...

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution ...

The diagnostics advisory committee reviewed the evidence available on the clinical and cost effectiveness of epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing to inform first ...

This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line treatment of patients with EGFR-mutated NSCLC 1 In the Phase 3 MARIPOSA study ...

First-line treatment of EGFR mutation adenosquamous carcinoma of the lung with aumolertinib: A multicenter, single-arm, prospective study (ARISE Study). This is an ASCO Meeting Abstract from the 2024 ...

BEERSE, BELGIUM, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II variation ...

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...

The human epidermal growth-factor receptor (EGFR) inhibitor afatinib (Boehringer Ingelheim), which is under priority review at the US Food and Drug Administration (FDA), could be considered a ...

RARITAN, N.J., March 20, 2025 /PRNewswire/ -- Johnson & Johnson (JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer ...